


(R)-Azasetron besylate

Cat. No.:	HY-B0019C
CAS No.:	2025360-91-0
Molecular Formula:	C ₂₃ H ₂₆ ClN ₃ O ₆ S
Molecular Weight:	507.99
Target:	Phosphatase
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 200 mg/mL (393.71 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9685 mL	9.8427 mL	19.6854 mL
	5 mM	0.3937 mL	1.9685 mL	3.9371 mL
	10 mM	0.1969 mL	0.9843 mL	1.9685 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 20 mg/mL (39.37 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 20 mg/mL (39.37 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 20 mg/mL (39.37 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

(R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage^{[1][2]}.

REFERENCES

- [1]. Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours. *Otol Neurotol.* 2019 Feb;40(2):254-263.

[2]. Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. *Otol Neurotol*. 2017 Oct;38(9):1355-1361.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA